<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04157920</url>
  </required_header>
  <id_info>
    <org_study_id>DIRECT II</org_study_id>
    <nct_id>NCT04157920</nct_id>
  </id_info>
  <brief_title>Impact of Predilatation Between Self-expanding Valves</brief_title>
  <acronym>DIRECTII</acronym>
  <official_title>Impact of Balloon Predilatation Between Self-expanding Valves in All Comers Undergoing TAVI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National and Kapodistrian University of Athens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Naval Hospital, Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Silesian Centre for Heart Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University General Hospital of Heraklion</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Interbalkan Medical Center, Thessaloniki, Greece</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National and Kapodistrian University of Athens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, prospective, non-randomized, trial evaluating the safety and clinical efficacy&#xD;
      of the next-generation, self-expandable Boston Scientific ACURATE NEO/TF Transcatheter Heart&#xD;
      Valves, implanted in patients with severe aortic stenosis and the impact of predilatation in&#xD;
      comparison with the Medtronic CoreValve EvolutT R/PRO systems from the DIRECT trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the present prospective, multicenter, non-randomized trial is to compare the&#xD;
      device success rate and the in-hospital and 30-day safety and echocardiographic clinical&#xD;
      outcomes between TAVI with and without predilatation in all comers undergoing implantation of&#xD;
      self-expanding valves. Primary endpoint will be device success rate as defined by the VARC-2&#xD;
      criteria. Secondary endpoints involve the composite endpoint of early safety at 30 days,&#xD;
      according to the VARC-2 definitions, specifically all cause mortality, cardiovascular&#xD;
      mortality, stroke, acute kidney injury, life-threatening or disabling bleeding, major&#xD;
      vascular complication, as well as the echocardiographic outcomes and valve performance as&#xD;
      designated by the VARC-2 definitions at 30 days. VARC-1 and VARC-3 device success rates will&#xD;
      be estimated as well.&#xD;
&#xD;
      Study type: Observational&#xD;
&#xD;
      Estimated Enrollment: 75 patients&#xD;
&#xD;
      Allocation: Non - randomized, all comers&#xD;
&#xD;
      Primary Purpose: Treatment&#xD;
&#xD;
      Observational Model: Case-Control&#xD;
&#xD;
      Condition or disease: Aortic valve stenosis&#xD;
&#xD;
      Intervention/Treatment: Device: Boston Scientific ACURATE neoTM transfemoral TAVI system&#xD;
&#xD;
      Time Perspective: Prospective&#xD;
&#xD;
      Participating centers: Hippokration Hospital (Athens, Greece), Silesian Center for Heart&#xD;
      Diseases (Zabrze, Poland), Athens Naval Hospital (Athens, Greece). It is possible that the&#xD;
      number of the participating center may change.&#xD;
&#xD;
      Methods: Patients treated with the Boston Scientific ACURATE NEO/TF system will be&#xD;
      prospectively. All patients will be followed for at least 30 days. A primary study by Pagnesi&#xD;
      et al. estimated the device success rate by ACURATE neo valve at 83% whereas Toutouzas et al.&#xD;
      estimated the device success rate by Medtronic CoreValve/Evolut R/PRO at 76% (6, 17). Taking&#xD;
      83% as our point estimate, the steering committee of DIRECT II considers that ACURATE neo&#xD;
      valve can be regarded as non-inferior to Medtronic CoreValve/Evolut R/PRO if the lower margin&#xD;
      of the confidence interval does not lies under the rate of 83% by more than 5% (i.e. if it is&#xD;
      not lower than 78%). Based on these assumptions, an expected sample size of 65 patients is&#xD;
      required to achieve 80% power to demonstrate the efficacy of ACURATE neo valve, when type I&#xD;
      error rate is set at 0.05. To eliminate possible impact of a small dropout rate, a total of&#xD;
      78 patients were recruited&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 17, 2019</start_date>
  <completion_date type="Anticipated">December 20, 2021</completion_date>
  <primary_completion_date type="Actual">April 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients undergoing TAVR for severe aortic stenosis with two different transcatheter devices. One arm received Medtronic Evolut R/Pro. The other is receiving Boston Scientific ACURATE NEO/TF</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Device success</measure>
    <time_frame>30 days</time_frame>
    <description>ACURATE NEO/TF device implantation success rates, as designated by the VARC-2 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Death teates during the hospitalization of the patient, as designated by the VARC-2 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All stroke</measure>
    <time_frame>30 days</time_frame>
    <description>Cerebrovascular accident rates during and after the hospitalization of the patient, as designated by the VARC-2 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New pacemaker implantation</measure>
    <time_frame>30 days</time_frame>
    <description>New pacemaker implantation rates during and after the hospitalization of the patient, as designated by the VARC-2 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Vascular complications</measure>
    <time_frame>30 days</time_frame>
    <description>Vascular complications rates during and after the hospitalization of the patient, as designated by the VARC-2 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic endpoint</measure>
    <time_frame>30 days</time_frame>
    <description>Echocardiographic endpoint (Post TAVI aortic valve area in cm2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dilatation</measure>
    <time_frame>30 days</time_frame>
    <description>Post-dilatation rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>30 days</time_frame>
    <description>Major bleeding during and after the hospitalization of the patient, as designated by the VARC-2 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute kidney injury stage 2 or 3</measure>
    <time_frame>30 days</time_frame>
    <description>AKI stage 2 or 3 during and after the hospitalization of the patient, as designated by the VARC-2 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>30 days</time_frame>
    <description>ACURATE NEO/TF device implantation success rates, as designated by the VARC-1 and VARC-3 criteria</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Patients treated with Medtronic CoreValve/ Evolut R/Pro</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>TAVI patients treated with Medtronic CoreValve /Evolut R - Evolut PRO Transcatheter Heart Valves, participated in the DIRECT trial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients treated with ACURATE neo/TF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAVI patients treated with ACURATE neo/TF Transcatheter Heart Valve recruited prospectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Aortic Valve Implantation with ACURATE NEO/TF</intervention_name>
    <description>Transcatheter implantation of the heart valve device ACURATE neo/TF in patients suffering from severe aortic stenosis and are candidates for this operation</description>
    <arm_group_label>Patients treated with ACURATE neo/TF</arm_group_label>
    <other_name>Boston Scientific ACURATE neo/TF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Aortic Valve Implantation with Medtronic CoreValve /Evolut R/Pro</intervention_name>
    <description>Transcatheter implantation of the heart valve device Medtronic Evolut R/Pro in patients suffering from severe aortic stenosis and are candidates for this operation</description>
    <arm_group_label>Patients treated with Medtronic CoreValve/ Evolut R/Pro</arm_group_label>
    <other_name>Medtronic CoreValve /Evolut R/Pro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with severe symptomatic aortic stenosis defined by a mean aortic gradient &gt; 40&#xD;
             mmHg or peak jet velocity &gt; 4.0 m/s or an aortic valve area (AVA) &lt; 1cm2 or AVA&#xD;
             indexed to body surface area (BSA) of &lt;0.6 cm2/m2&#xD;
&#xD;
          -  Patient is symptomatic (heart failure with New York Heart Association (NYHA)&#xD;
             Functional Class &gt; I, angina or syncope)&#xD;
&#xD;
          -  Patients are considered at high risk for mortality with conventional surgical aortic&#xD;
             valve replacement as assessed by a Heart Team consisting of a cardiologist and surgeon&#xD;
             or as confirmed by a logistic EuroSCORE I ≥ 20% and / or EuroSCORE II ≥ 7% STS score ≥&#xD;
             8% OR&#xD;
&#xD;
          -  Over 80 years old OR&#xD;
&#xD;
          -  Over 65 years old with 1 or 2 (but not more than two) from the following criteria:&#xD;
&#xD;
        Liver cirrhosis (Class A or B). Pulmonary insufficiency: VMS&lt;1 liter. Previous heart&#xD;
        surgery (CABG, vascular surgery). Porcelain aorta. Pulmonary artery systolic pressure &gt;60&#xD;
        mmHg and high risk for heart surgery. Relapsing pulmonary embolism. Right ventricular&#xD;
        insufficiency. Thoracic wall injuries that contraindicate an open heart surgery. History of&#xD;
        radiation therapy of the mediastinum. Connective tissue disease that contraindicates an&#xD;
        open heart surgery. Frailty/cachexia.&#xD;
&#xD;
          -  Aortic valve diameter of ≥20mm and ≤2 9mm as measured by echo.&#xD;
&#xD;
          -  Ascending aorta diameter ≤ 43 mm at the sinotubular junction.&#xD;
&#xD;
          -  Arterial aorto-iliac-femoral axis suitable for transfemoral access as assessed by&#xD;
             conventional angiography and/or multi-detector computed tomographic angiography&#xD;
             (access vessel diameter ≥ 6mm)&#xD;
&#xD;
          -  Patient understands the purpose, the potential risks as well as benefits of the trial&#xD;
             and is willing to participate in all parts of the follow-up&#xD;
&#xD;
          -  Patient has given written consent to participate in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A known hypersensitivity or contraindication to any of the following which cannot be&#xD;
             adequately pre-medicated: aspirin or heparin and bivalirudin, ticlodipine and&#xD;
             clopidogrel, nitinol (titanium or nickel), contrast media&#xD;
&#xD;
          -  Ongoing sepsis, including active endocarditis.&#xD;
&#xD;
          -  Any percutaneous coronary or peripheral interventional procedure with a bare metal or&#xD;
             drug eluting stent performed within 30 days prior to Heart Team assessment.&#xD;
&#xD;
          -  Echocardiographic evidence of LV or LA thrombus.&#xD;
&#xD;
          -  Mitral or tricuspid valve insufficiency (&gt; grade II).&#xD;
&#xD;
          -  Previous aortic valve replacement (mechanical or bioprosthetic).&#xD;
&#xD;
          -  Recent (within 6 months of Heart Team assessment) cerebrovascular accident (CVA) or&#xD;
             transient ischemic attack (TIA).&#xD;
&#xD;
          -  Patients with:&#xD;
&#xD;
        Femoral, iliac or aortic vascular disease (stenosis etc) that precludes the insertion of a&#xD;
        transcatheter sheath.&#xD;
&#xD;
        OR Symptomatic carotid or vertebral artery disease (&gt; 70% stenosis).&#xD;
&#xD;
          -  The patient has a bleeding diathesis, coagulopathy or denies blood transfusion.&#xD;
&#xD;
          -  Estimated life expectancy of less than 12 months due to associated non-cardiac&#xD;
             co-morbid conditions.&#xD;
&#xD;
          -  Creatinine clearance &lt; 20 ml/min.&#xD;
&#xD;
          -  Active gastritis or gastrointestinal ulcer.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Severe left ventricular dysfunction with left ventricular ejection fraction (LVEF) &lt;&#xD;
             20%.&#xD;
&#xD;
          -  Unicuspid aortic valve.&#xD;
&#xD;
          -  Mixed aortic valve disease (aortic stenosis and aortic regurgitation&gt; 2+).&#xD;
&#xD;
          -  Liver failure (Child-Pugh class C).&#xD;
&#xD;
          -  Severe dementia (resulting in either inability to provide informed consent for the&#xD;
             study/procedure, prevents independent lifestyle outside of a chronic care facility, or&#xD;
             will fundamentally complicate rehabilitation from the procedure or compliance with&#xD;
             follow-up visits).&#xD;
&#xD;
          -  Extreme aortic valve calcification and calcific asymmetry (Agatston score: grade 4&#xD;
             AgS&gt;5000 AU).&#xD;
&#xD;
          -  Aortic valve area of &lt; 0.4 cm2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konstantinos P Toutouzas, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Professor of Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hippocration Hospital First Department of Cardiology, University of Athens, Medical School</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Arora S, Strassle PD, Ramm CJ, Rhodes JA, Vaidya SR, Caranasos TG, Vavalle JP. Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Lower Surgical Risk Scores: A Systematic Review and Meta-Analysis of Early Outcomes. Heart Lung Circ. 2017 Aug;26(8):840-845. doi: 10.1016/j.hlc.2016.12.003. Epub 2017 Jan 24. Review.</citation>
    <PMID>28169084</PMID>
  </reference>
  <reference>
    <citation>Adams HSL, Ashokkumar S, Newcomb A, MacIsaac AI, Whitbourn RJ, Palmer S. Contemporary review of severe aortic stenosis. Intern Med J. 2019 Mar;49(3):297-305. doi: 10.1111/imj.14071. Review.</citation>
    <PMID>30091235</PMID>
  </reference>
  <reference>
    <citation>Saikrishnan N, Kumar G, Sawaya FJ, Lerakis S, Yoganathan AP. Accurate assessment of aortic stenosis: a review of diagnostic modalities and hemodynamics. Circulation. 2014 Jan 14;129(2):244-53. doi: 10.1161/CIRCULATIONAHA.113.002310. Review. Erratum in: Circulation. 2014 Oct 7;130(15):e136.</citation>
    <PMID>24421359</PMID>
  </reference>
  <reference>
    <citation>4. Piérard L. Transcatheter aortic valve implantation: indications. E-Journal of Cardiology Practice [Internet]. 2016 5 May 2019 [cited 2019 5 May 2019]; Volume 14 Available from: https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-14/transcatheter-aortic-valve-implantation-indications</citation>
  </reference>
  <reference>
    <citation>Möllmann H, Diemert P, Grube E, Baldus S, Kempfert J, Abizaid A. Symetis ACURATE TF™ aortic bioprosthesis. EuroIntervention. 2013 Sep 10;9 Suppl:S107-10. doi: 10.4244/EIJV9SSA22.</citation>
    <PMID>24025946</PMID>
  </reference>
  <reference>
    <citation>Manoharan G, Walton AS, Brecker SJ, Pasupati S, Blackman DJ, Qiao H, Meredith IT. Treatment of Symptomatic Severe Aortic Stenosis With a Novel Resheathable Supra-Annular Self-Expanding Transcatheter Aortic Valve System. JACC Cardiovasc Interv. 2015 Aug 24;8(10):1359-1367. doi: 10.1016/j.jcin.2015.05.015.</citation>
    <PMID>26315740</PMID>
  </reference>
  <reference>
    <citation>Forrest JK, Mangi AA, Popma JJ, Khabbaz K, Reardon MJ, Kleiman NS, Yakubov SJ, Watson D, Kodali S, George I, Tadros P, Zorn GL 3rd, Brown J, Kipperman R, Saul S, Qiao H, Oh JK, Williams MR. Early Outcomes With the Evolut PRO Repositionable Self-Expanding Transcatheter Aortic Valve With Pericardial Wrap. JACC Cardiovasc Interv. 2018 Jan 22;11(2):160-168. doi: 10.1016/j.jcin.2017.10.014.</citation>
    <PMID>29348010</PMID>
  </reference>
  <reference>
    <citation>Toutouzas K, Benetos G, Voudris V, Drakopoulou M, Stathogiannis K, Latsios G, Synetos A, Antonopoulos A, Kosmas E, Iakovou I, Katsimagklis G, Mastrokostopoulos A, Moraitis S, Zeniou V, Danenberg H, Vavuranakis M, Tousoulis D. Pre-Dilatation Versus No Pre-Dilatation for Implantation of a Self-Expanding Valve in All Comers Undergoing TAVR: The DIRECT Trial. JACC Cardiovasc Interv. 2019 Apr 22;12(8):767-777. doi: 10.1016/j.jcin.2019.02.005. Epub 2019 Mar 27.</citation>
    <PMID>30928442</PMID>
  </reference>
  <reference>
    <citation>Pagnesi M, Kim WK, Conradi L, Barbanti M, Stefanini GG, Zeus T, Pilgrim T, Schofer J, Zweiker D, Testa L, Taramasso M, Hildick-Smith D, Abizaid A, Wolf A, Van Mieghem NM, Sedaghat A, Wöhrle J, Khogali S, Van der Heyden JAS, Webb JG, Estévez-Loureiro R, Mylotte D, MacCarthy P, Brugaletta S, Hamm CW, Bhadra OD, Schäfer U, Costa G, Tamburino C, Cannata F, Reimers B, Veulemans V, Asami M, Windecker S, Eitan A, Schmidt A, Bianchi G, Bedogni F, Saccocci M, Maisano F, Alsanjari O, Siqueira D, Jensen CJ, Naber CK, Ziviello F, Sinning JM, Seeger J, Rottbauer W, Brouwer J, Alenezi A, Wood DA, Tzalamouras V, Regueiro A, Colombo A, Latib A. Transcatheter Aortic Valve Replacement With Next-Generation Self-Expanding Devices: A Multicenter, Retrospective, Propensity-Matched Comparison of Evolut PRO Versus Acurate neo Transcatheter Heart Valves. JACC Cardiovasc Interv. 2019 Mar 11;12(5):433-443. doi: 10.1016/j.jcin.2018.11.036.</citation>
    <PMID>30846081</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2019</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National and Kapodistrian University of Athens</investigator_affiliation>
    <investigator_full_name>Konstantinos Toutouzas</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Aortic stenosis</keyword>
  <keyword>DIRECT</keyword>
  <keyword>ACURATE</keyword>
  <keyword>TAVI</keyword>
  <keyword>TAVR</keyword>
  <keyword>transcatheter</keyword>
  <keyword>valve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

